UNITED THERAPEUTICS (UTHR) stock, explained like you're 5

Is UNITED THERAPEUTICS a small, medium or large cap company?

Yes. UNITED THERAPEUTICS is a large cap stock. Its market cap, which is the total value of all its shares, is about 23.6 billion dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How UNITED THERAPEUTICS makes money

• Selling medicines, medical devices or healthcare services.
• Insurance premiums or hospital and clinic fees.
• Research and licensing deals.

What moves UTHR stock

• Results from clinical trials and approvals from regulators.
• Drug prices, insurance rules and government policy.
• Patents running out and new competing treatments.

In the news lately

• StockWatch: Liquidia Rebounds After Settling Legal Wrangle with United Therapeutics (Genetic Engineering and Biotechnology News)
• United Therapeutics (UTHR) Stock May Be Undervalued Following The Litigation Settlement (Yahoo Finance)
• Liquidia surges as United Therapeutics settlement removes key litigation risk (Reuters)
• Liquidia And United Therapeutics Settle; But Only One Stock Skyrocketed (Investor's Business Daily)
• An 8,300 share planned sale follows an option exercise by United Therapeutics (UTHR) counsel. (Stock Titan)

Key terms to know before you follow UTHR

• Market cap
• P/E ratio
• EPS (earnings per share)
• Earnings report
• Volatility